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SUMF1(MSD), mucolipidosis (ML) II/III and Niemann–Pick type C1 (NPC1) disease are
rare but fatal lysosomal storage disorders caused by the genetic defect of non-lysosomal proteins. The NPC1
protein mainly localizes to late endosomes and is essential for cholesterol redistribution from endocytosed
LDL to cellular membranes. NPC1 deﬁciency leads to lysosomal accumulation of a broad range of lipids. The
precise functional mechanism of this membrane protein, however, remains puzzling. ML II, also termed I cell
disease, and the less severe ML III result from deﬁciencies of the Golgi enzyme N-acetylglucosamine 1-
phosphotransferase leading to a global defect of lysosome biogenesis. In patient cells, newly synthesized
lysosomal proteins are not equipped with the critical lysosomal trafﬁcking marker mannose 6-phosphate,
thus escaping from lysosomal sorting at the trans Golgi network. MSD affects the entire sulfatase family, at
least seven members of which are lysosomal enzymes that are speciﬁcally involved in the degradation of
sulfated glycosaminoglycans, sulfolipids or other sulfated molecules. The combined deﬁciencies of all
sulfatases result from a defective post-translational modiﬁcation by the ER-localized formylglycine-
generating enzyme (FGE), which oxidizes a speciﬁc cysteine residue to formylglycine, the catalytic residue
enabling a unique mechanism of sulfate ester hydrolysis. This review gives an update on the molecular bases
of these enigmatic diseases, which have been challenging researchers since many decades and so far led to a
number of surprising ﬁndings that give deeper insight into both the cell biology and the pathobiochemistry
underlying these complex disorders. In case of MSD, considerable progress has been made in recent years
towards an understanding of disease-causing FGE mutations. First approaches to link molecular parameters
with clinical manifestation have been described and even therapeutical options have been addressed.
Further, the discovery of FGE as an essential sulfatase activating enzyme has considerable impact on enzyme
replacement or gene therapy of lysosomal storage disorders caused by single sulfatase deﬁciencies.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
Lysosomal storage disorders (LSDs) arise when one or several
lysosomal proteins, in particular catabolic hydrolases, are deﬁcient, so
that the substrates of the affected enzyme(s) are no longer degradedSD); NPC1 – OMIM: 607623,
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ll rights reserved.and thus accumulate. Apart from the many speciﬁc lysosomal enzyme
deﬁciencies there are two fatal diseases in which an entire family or
even the majority of all lysosomal enzymes do not fulﬁll their
functions. Both syndromes, mucolipidoses (ML) II/III and multiple
sulfatase deﬁciency (MSD), result from deﬁciencies of speciﬁc post-
translational modiﬁcations, namely the generation of mannose 6-
phosphate or Cα-formylglycine (FGly) residues, respectively.Mannose
6-phosphate is introduced into the majority of newly synthesized
lysosomal enzymes in the Golgi apparatus, while FGly modiﬁcation of
nascent sulfatases occurs in the ER. Niemann–Pick type C1 (NPC1)
disease is a third LSD originating from the defect of a largely non-
lysosomal protein. The NPC1 protein localizes mainly to late endo-
somes and fulﬁlls an unknown function, deﬁciency of which leads to
lysosomal accumulation of a broad range of lipids.
Table 1
Classiﬁcation of mucolipidoses II and III
OMIM catalog numbers (Online Mendelian Inheritance in Man, John Hopkins
University) and prevalence of the mucolipidoses per 100,000 births according to [9].
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can guide scientists to discover fundamental new aspects in basic
research, which in turn have direct impact for therapy. The key ﬁnding
that MSD patient cells express wild-type cDNAs yielding full-length
sulfatase polypeptides that, however, lack enzymatic activity [1] led to
the prediction and, ﬁnally, discovery of a novel post-translational
modiﬁcation of sulfatases, namely the generation of FGly by oxidation
of a speciﬁc cysteine residue [2]. The critical role of this novel amino
acid and its highly reactive and, in effect, toxic formyl group was later
understood to originate from the formation of a (non-toxic) aldehyde
hydrate within the active site of sulfatases carrying two geminal
hydroxyl groups which both are required for sulfatase ester hydrolysis
according to a novel mechanism [3,4]. In fact, the hydrate water
molecule allows for an ‘intramolecular hydrolysis’ of a covalent sulfo-
enzyme intermediate without the requirement of activating an
‘external’ water molecule, e.g., by metal ions as employed by other
esterases [5].
Also FGE, the enzyme generating this unusual amino acid, was and
still is full of surprises both with regard to its structure and function as
a metal-independent oxygenase and its unusual cell biology, as is
described in further detail below. Of the ﬁndings so far, two aspects
had immediate relevance for therapeutic options. The ﬁnding that FGE
is secreted, taken up by other cells and transported all the way back to
the ER of recipient cells [6] is the basis for a scenario to apply FGE in
enzyme replacement therapy to treat MSD, a rather unusual approach
for an enzyme defect of the ER. Secondly, FGE already now is an
important tool for the production of highly active sulfatases to be used
for enzyme replacement therapy of lysosomal storage disorders
caused by single sulfatase deﬁciencies [7] (M. Heartlein, personal
communication).
Thus, multiple lessons have been learned from MSD so far, which
underlines the general importance of studying inherited diseases even
if only very few patients are affected. On the other hand, many
questions need to be answered to unravel the steps from the basic
molecular defect to the manifestation of the disease, each step with
the potential to be targeted for therapeutic purposes and, altogether,
to gain deeper insight into complex pathophysiological mechanisms.
Some of these issues will be illustrated below for MSD, and in less
depth, also for ML II/III and NPC1-disease, three lysosomal storage
disorders caused by deﬁciencies of non-lysosomal key players in cell
biology (though in the case of NPC1 the precise role awaits to be
uncovered).
2. Mucolipidoses II/III — diseases of lysosomal protein trafﬁcking
The mucolipidoses ML II alpha/beta, ML III alpha/beta and ML III
gamma are three related autosomal-recessive lysosomal storage
disorders in which the transport of newly synthesized lysosomal
proteins to the lysosomes is impaired due to a genetic defect of the
Golgi enzyme uridine diphosphate (UDP)-N-acetylglucosamine:lyso-
somal enzyme N-acetylglucosamine 1-phosphotransferase (EC
2.7.8.15), commonly termed GlcNAc phosphotransferase [8]. Although
these diseases are rare in occurrence (see Table 1), they have provided
important insight into the transport of lysosomal hydrolases [9,10].
The recent reclassiﬁcation of the ML II and ML III disorders has
replaced the previous nomenclature as shown in Table 1 [11].
2.1. Molecular and cell biological basis of ML II/III
In higher eukaryotes, most lysosomal hydrolases are targeted to
the lysosomes via the mannose 6-phosphate pathway which requires
the posttranslational modiﬁcation of newly synthesized lysosomal
proteins with mannose 6-phosphate as a recognition marker
(reviewed in [12]). As depicted in Fig. 1, along the biosynthetic
pathway the mannose 6-phosphate residue is generated in two
subsequent enzymatic reactions [13]. Following N-glycosylation ofasparagine residues in the ER, GlcNAc phosphotransferase in the Golgi
catalyzes the transfer of GlcNAc 1-phosphate to the C6 position of
selected α1,2-linked mannose residues on high mannose-type
oligosaccharides [14–17]. The topogenic structure required for the
recognition of lysosomal hydrolases by GlcNAc phosphotransferase is
still not well deﬁned. The presence of adequately spaced lysine
residues appears to be necessary, although no common recognition
motif could be identiﬁed even among closely related lysosomal
enzymes [18]. In the second step, the mannose 6-phosphate marker is
exposed via removal of the N-acetylglucosamine residue by the
uncovering enzyme N-acetylglucosamine 1-phosphodiester N-acet-
ylglucosaminidase (NAGPA, EC 3.1.4.45) localized in the trans Golgi
network [19,20]. Subsequently, lysosomal proteins can be recognized
by the mannose 6-phosphate receptors (MPR46/MPR300) and
shuttled to early or late endosomes where they dissociate from their
receptors due to the low pH and are further transported to the
lysosomes (reviewed in [21]). Interestingly, inherited genetic dis-
orders are only known for GlcNAc phosphotransferase, but not for the
uncovering enzyme NAGPA [10,19].
GlcNAc phosphotransferase has been characterized as an enzyme
complex with a hexameric α2β2γ2 subunit structure [22]. It has been
suggested that the α and β subunits contain the catalytic activity,
whereas the γ subunit is responsible for the recognition of lysosomal
proteins [8,23]. The subunits of the enzyme are encoded by two genes,
GNPTA (also termed GNPTAB) and GNPTG. The GNPTA gene is located
on chromosome 12q23.3 and encodes an αβ precursor protein with a
complex modular domain structure of 1256 amino acid residues that
is proteolytically processed to release the α and β subunits, both
equipped with a transmembrane domain [24,25]. The gene GNPTG
localizes to chromosome 16p13.3 and codes for the γ subunit, a
soluble protein of 305 amino acid residues that associates with the α/
β subunits, yielding a membrane-bound enzyme complex of 540 kDa
in the cis Golgi [22,23,25].
Mutations in the GNPTA gene as observed in ML II alpha/beta and
ML III alpha/beta result in a reduction of GlcNAc phosphotransferase
activity [24–31]. As a consequence, the lysosomal proteins lacking
mannose 6-phosphate residues are unable to bind to mannose 6-
phosphate receptors, resulting in hypersecretion into the extracellular
space and the body ﬂuids instead of lysosomal targeting. Similar to
other LSDs, undigested macrocompounds accumulate in the lyso-
somes. Total or near-total deﬁciency of GlcNAc phosphotransferase
leads to ML II alpha/beta, the clinically more severe form. ML III is
genetically heterogeneous [32]. In the case of ML III alpha/beta,
GlcNAc phosphotransferase activity is reduced rather than absent,
resulting in a milder phenotype compared to ML II alpha/beta [8].
Mutations in the gene encoding the γ subunit, GNPTG, are
responsible for ML III gamma [23,33]. This variant is characterized
by normal activity of GlcNAc phosphotransferase towards the small
pseudosubstrate α-methyl mannoside but reduced activity towards
native lysosomal hydrolases as substrates [34,35]. Studies with knock
out mice lacking either GNPTA or GNPTG have shown that the loss of
the α/β subunits completely abolishes formation of mannose 6-
Fig. 1. Lysosomal storage disorders caused by deﬁciencies of non-lysosomal proteins. The illustration summarizes the molecular bases of Niemann–Pick disease type C (NPC),
mucolipidoses II and III (ML II/III) and multiple sulfatase deﬁciency (MSD) (see text for details). In case of NPC, the intracellular redistribution of LDL-derived cholesterol from
lysosomes to the ER and plasma membrane is impaired due to a genetic defect of either NPC1, a transmembrane protein localized mainly in endosomes, but also in the TGN or
lysosomes, or in rare cases of NPC2, a soluble lysosomal protein. The loss of either protein leads to lysosomal storage of unesteriﬁed cholesterol and gangliosides. ML II and ML III are
disorders caused by a deﬁciency of GlcNAc phosphotransferase (GlcNAc-PT), a Golgi enzyme required for generation of the mannose 6-phosphate recognitionmarker that directs the
targeting of lysosomal proteins via the mannose 6-phosphate receptor pathway. Because lysosomal hydrolases cannot reach their destination, undigested storage material
accumulates within lysosomes. Also in MSD lysosomal storage (of sulfatedmolecules) results from a defect in post-translational modiﬁcation of hydrolytic enzymes, which is speciﬁc
for the family of the sulfatases. MSD is caused by a genetic deﬁciency of FGE, the formylglycine generating enzyme. FGE localizes to the ER and catalyzes the oxidation of a speciﬁc
cysteine residue of newly synthesized sulfatases to the active site Cα-formylglycine residue, which is essential for enzymatic activity.
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occurs in the absence of the γ subunit [36]. Therefore it was proposed
that the α/β subunits, in addition to their catalytic function, interact
with lysosomal hydrolases and that this recognition is enhanced by
the γ subunit. Also a possible role of the γ subunit in facilitating
protein folding or maintaining enzyme conformation has been
discussed [37]. Intriguingly, there is no direct evidence of interactions
between the γ subunit and lysosomal proteins [37], making an
understanding of the pathomechanisms of ML III gamma even more
difﬁcult.
2.2. Clinical features, diagnosis and therapeutic approaches
The term mucolipidosis refers to the clinically observed combi-
nation of the symptoms of mucopolysaccharidoses and sphingolipi-
doses [38,39]. In most cases of ML II alpha/beta, defects are apparent
from early infancy or even prenatally. Patients are typically
characterized by dwarﬁsm, coarse facies, stiffness of the joints,
skeletal abnormalities, cardio- and hepatomegaly and mental
retardation. One of the most characteristic histological features is
the presence of enlarged lysosomes ﬁlled with undigested com-
pounds in patient ﬁbroblasts, also called inclusion- or I-cells [40]. MLII alpha/beta has a fatal outcome usually between 5 and 8 years of
age due to congestive heart failure and/or recurrent pulmonary
infections [8]. The variability in clinical symptoms of the mucolipi-
doses corresponds to differences in residual GlcNAc phosphotrans-
ferase activities, resulting in a wide spectrum of severity from
prenatally lethal [41] to progressive ML II alpha/beta and mild adult
onset forms of ML III alpha/beta [28,42].
ML III was ﬁrst described as pseudo Hurler polydystrophy due to
similarities with the Hurler syndrome (MPS-IH) caused by a genetic
deﬁciency of α-iduronidase [43]. In a series of genetic complementa-
tion experiments with patient ﬁbroblasts [44], different complemen-
tation groups were identiﬁed, corresponding to ML III alpha/beta and
ML III gamma [11]. Clinical symptoms of ML III alpha/beta and ML III
gamma are indistinguishable and represent a mild and attenuated
form of ML II alpha/beta. BothML III forms are characterized by a later
onset, at the age of 2 to 4 years, and a more slowly progressive course,
permitting patient survival into the eighth decade [45,46]. About 50%
of reported patients have learning disabilities or mental retardation.
Skeletal dysplasia and especially destruction of the hip joints are most
disabling symptoms of the ML III disorders [8]. Residual GlcNAc
phosphotransferase activities in ML III alpha/beta are reported to be 2
to 20% of normal values [8,34,45].
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genetic techniques. The enzymatic activities of different lysosomal
hydrolases are severely decreased in ﬁbroblasts of affected patients,
whereas they aremarkedly increased in serum or cell culturemedium.
Sequencing of the impaired genes will conﬁrm the diagnosis and
identify the underlying mutations, which are the basis for genetic
counseling. Both mucolipidoses ML II and ML III can be diagnosed
prenatally [47–49], but no etiological therapies are currently available
for their treatment. Studies with a limited number of ML II alpha/beta
patients have described bone marrow transplantations as beneﬁcial
with regard to improving neurodevelopment and cardiopulmonary
complications, although the underlying mechanisms remain unclear
[50,51]. In the case of ML III, treatment with bisphosphonate
pamidronate has been reported to reduce bone pain and to improve
mobility [52].
Since GlcNAc phosphotransferase is a membrane-bound enzyme
complex localized in the Golgi apparatus, enzyme replacement
therapy as practiced for LSDs caused by deﬁciencies of soluble
lysosomal hydrolases is not likely to be successful. Instead, gene
therapy might represent a promising approach as indicated by initial
experiments using retroviral transduction [25]. In this study, the
GNPTA gene was successfully expressed in ﬁbroblasts from an ML
II alpha/beta patient, resulting in Golgi localization of GlcNAc
phosphotransferase and correction of hypersecretion of lysosomal
hydrolases.
3. Niemann–Pick C1 disease — a disease of subcellular
lipid transport
Niemann–Pick type C (NPC) disease is an autosomal-recessive
lysosomal lipid storage disorder. According to the most widely
accepted model, NPC is caused by an impaired redistribution of LDL-
derived cholesterol from the endocytic compartments to the ER and
the plasma membrane (extensively reviewed in [53–58]). NPC
represents a rare, genetically heterogeneous disease resulting from
mutations in either the NPC1 gene (MIM# 257220, in 95% of the cases)
or the NPC2 gene (MIM# 607625). Biochemically, NPC is not related to
the Niemann–Pick type A and B diseases which are due to genetic
defects of the lysosomal enzyme sphingomyelinase [59]. Whereas the
NPC2 gene product represents a classical lysosomal protein, NPC1
predominantly localizes to late endosomes [60,61]. NPC1 disease can
therefore be considered, although less strictly than in case of MSD and
ML II/III, as a lysosomal storage disorder caused by a defect outside of
the lysosomes.
3.1. Molecular and cell biological basis of NPC
Under normal physiological conditions, extracellular low-density
lipoproteins (LDL) are recognized by LDL receptors on the cell surface,
internalized and transported to the lysosomes, where LDL-derived
cholesteryl esters are hydrolyzed [62–65]. The released cholesterol is
redistributed to the ER and to the plasma membrane, as illustrated in
Fig. 1. Although the underlying mechanisms are still unclear, both
NPC1 and NPC2 proteins are involved in the egress of cholesterol from
late-endosomes/lysosomes and in intracellular cholesterol home-
ostasis. Deﬁciency of either the NPC1 or NPC2 protein leads to a
massive lysosomal storage of unesteriﬁed cholesterol, sphingosine,
glycosphingolipids and bis(monoacylglycerol)phosphate mainly in
the liver and spleen.
Although no overt cholesterol accumulation is observed in the
brain, NPC results in a progressive and ﬁnally fatal degeneration of
the central nervous system, probably due to lysosomal storage of
cholesterol and gangliosides and extensive demyelination of axons
[53,58]. Demyelination may also mask an actual increase in neuronal
cholesterol content. Although in the brain all cholesterol has to be
synthesized endogenously, in NPC it accumulates in the endosomal/lysosomal system, because the plasma membrane constantly (and
physiologically) undergoes endocytosis. A disturbed cholesterol (and
ganglioside) homeostasis may subsequently result from a defective
subcellular redistribution/transport of lipids from the lysosomes to
other cellular locations, e.g. axonal membranes [58]. Alternatively,
the restricted accumulation of cholesterol in speciﬁc cell types of
the brain might lead to the observed neurological phenotype.
Nevertheless, it remains cryptic why NPC is primarily a neurological
disorder.
The NPC1 gene was identiﬁed in 1997 by positional cloning and
maps to chromosome 18q11 [66]. It encodes a large integral
membrane glycoprotein of 1278 amino acid residues that primarily
localizes to late endosomes and transiently also associates with
lysosomes and the trans-Golgi network [60,61]. It contains 13 putative
transmembrane spans, a sterol sensing domain and a di-leucine motif
at its cytoplasmic C-terminal tail which is required for late
endosomal/lysosomal targeting [67,68]. NPC1 binds cholesterol and
oxysterols at a site located on its luminal loop 1 [69,70]. The precise
function of NPC1 is still enigmatic. It has been proposed that NPC1
might act as a fatty acid permease [71], a cholesterol ﬂippase [72], a
cholesterol sensor or as part of a multi-protein complex that mediates
the egress of cholesterol from lysosomal membranes [56,58,73–75].
Moreover, a possible function of NPC1 in regulating lysosomal
concentrations of biogenic amines has been suggested [76]. NPC1
might also assist in partitioning of endocytic and lysosomal compart-
ments and facilitate endocytic transport [72]. Interestingly, a recent
study indicates that a loss of NPC1 is associated with decreased
lysosomal calcium concentrations, initially caused by storage of
sphingosine with subsequent accumulation of cholesterol, sphingo-
myelin and glycosphingolipids as downstream effects [77]. It is
proposed that sphingosine storage is the primary defect, which
inhibits calcium entry into the acidic compartment. Reduced calcium
levels then might lead to perturbation of vesicular trafﬁcking. In
normal cells, the addition of chelating agents that speciﬁcally reduce
endocytic calcium concentrations rapidly resulted in an NPC disease
cellular phenotype.Whether and howNPC1 is involved in sphingosine
transport remains a key question for future studies.
The NPC2 gene is localized on chromosome 14q24.3 [78]. In
contrast to NPC1, NPC2 is a small, soluble intralysosomal protein of 151
amino acid residues that contains a mannose 6-phosphate marker
[79]. It was originally identiﬁed as HE1, a major secretory protein of
human epididymis [80]. NPC2 binds cholesterol with submicromolar
afﬁnity and a 1:1 stoichiometry [81–83]. The crystal structure
demonstrates the presence of a deep hydrophobic binding pocket
that expands in the presence of sterols [82,84,85]. It has been
proposed that NPC2 functions as a cholesterol transporter in concert
with NPC1 [58]. Moreover, NPC2 is able to extract cholesterol from
donor membranes and catalyze the intermembrane transfer to
acceptor vesicles [86]. This could allow sorting of cholesterol from
internal lysosomal vesicles to the limiting membrane of the organelle.
3.2. Clinical features, diagnosis and therapeutic approaches
NPC has a highly variable phenotype regarding the age of onset,
severity of symptoms and progression of disease. Defects of either
NPC1 or NPC2 are clinically indistinguishable [53]. In most cases,
symptoms of NPC become evident in early childhood, usually between
4 and 12 years of age, and include dystonia, ataxia, seizures and
vertical gaze palsy [53,58]. Also neonatal jaundice and hepatospleno-
megaly are observed, leading to acute liver failure. Adult onset forms
are described in about 10% of NPC cases [87]. Histologically, NPC is
characterized by a loss of neurons, particularly Purkinje cells in the
cerebellum, extensive demyelination, the formation of meganeurites
and ectopic dendrites as well as the presence of neuroﬁbrillary tangles
similar to Alzheimer's disease [53,58]. Death typically occurs in
teenage years.
Fig. 2. FGly-mediated sulfate ester hydrolysis. The catalytic form of the FGly residue in
the sulfatase active site is the aldehyde hydrate (right), which is formed by addition of a
water molecule to the formyl group. Nucleophilic attack of the sulfate ester substrate by
one of the geminal hydroxyls of the aldehyde hydrate leads to transesteriﬁcation
(bottom) of the sulfate group onto the enzyme resulting in a sulfated FGly hemiacetal
intermediate (left). The second geminal hydroxyl group of this intermediate then reacts
to eliminate the sulfate, under cleavage of the C–O bond, and to regenerate the aldehyde
(top). For further details see [4].
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required to conﬁrm NPC. Diagnosis is best achieved by both
histopathological staining in cultured ﬁbroblasts for abnormal LDL-
cholesterol processing and biochemical assays. First, intralysosomal
accumulation of unesteriﬁed cholesterol, stained with ﬁlipin, is
detected by a characteristic perinuclear ﬂuorescence pattern after
challenging ﬁbroblasts with LDL [88], and second, abnormal intracel-
lular cholesterol homeostasis is proven as impairment of LDL-induced
cholesterol esteriﬁcation [53,88]. However, both methods show
deﬁcits in variant forms of NPC. Therefore molecular sequencing of
the impaired genes is necessary for conﬁrmation of the diagnosis as
well as for genetic counseling and prenatal testing. A continuously
updated database of NPC disease gene mutations including informa-
tion on functional consequences and phenotypes is accessible online
(NPC-db, http://npc.fzk.de, [89]).
Twomurine models of NPC with different genetic backgrounds are
available [90–93]. Analysis of the NPC1 or NPC2 deﬁcient mice did not
provide any indication for a possible role of the two proteins in
intestinal cholesterol adsorption [94]. In line with these results,
cholesterol-lowering agents or a dietary reduction of plasma
cholesterol unfortunately fail to slow the progression of the disease
[95]. At present, no etiological therapy for NPC is available. Current
treatments are largely symptomatic or preventive [53]. In case of
NPC1, enzyme replacement therapy is not applicable because of the
transmembrane architecture of the NPC1 protein and the neurological
phenotype. Accordingly, gene therapy is challenged by the efﬁcient
delivery of the NPC1 gene to its neuronal targets. On the other hand,
neuronal replacement by stem cell therapy [96] or substrate reduction
therapy [97] open up new therapeutic possibilities. Recent studies
with miglustat, a small iminosugar inhibitor of glucosylceramide
synthase, the enzyme catalyzing the ﬁrst committed step in the
biosynthesis of most glycosphingolipids, yielded promising results
and showed improvement or stabilization of clinical markers [98,99].
In contrast to NPC1, the small intralysosomal NPC2 appears as a
suitable candidate for enzyme replacement therapy, but clinical trials
are unlikely given the low frequency of occurrence. The recent ﬁnding
that NPC is characterized by a deregulation of lysosomal calcium
opens up new possibilities for therapeutic approaches [77]. Indeed, an
elevation of cytosolic calcium concentrations by high doses of
curcumin corrected the phenotype of NPC1 deﬁcient cells and led to
prolonged survival of NPC1 knock out mice.
4. Multiple sulfatase deﬁciency — a disease of post-translational
sulfatase modiﬁcation
Another lysosomal storage disorder caused by a non-lysosomal
protein ismultiple sulfatasedeﬁciency (MSD,MIM#272200). It is a rare
autosomal recessive disorderwith a prevalence of 1 in 1.4million births
[100]. MSD was ﬁrst described by Austin [101,102] as a variant form of
metachromatic leukodystrophy (MLD), since the patients analyzed
showed prevailing MLD characteristics and decreased arylsulfatase A
activity. However, the affected siblings of one family showed additional
clinical symptoms reminding of mucopolysaccharidosis as well as low
activities of arylsulfatases B and C and various lysosomal storage
material. Because of its compound clinical and biochemical appearance
the syndrome was later termed MSD [103,104].
Early complementation studies showed that the genetic deﬁciency
underlying MSD must be different from the defect in cells from single
sulfatase deﬁciencies [105–108]. Interestingly, the transduction of
MSD ﬁbroblasts with cDNAs encodingwildtype arylsulfatases A, B or C
resulted in the expression of sulfatase polypeptides with severely
diminished catalytic activity [1]. The sulfatases remained inactive
even after puriﬁcation to homogeneity excluding the possibility of a
tightly bound inhibitor. These ﬁndings led to the postulation of a post-
translational modiﬁcation that is common to and essential for
sulfatases to gain catalytic activity.4.1. Formylglycine — a novel amino acid allows for a unique hydrolytic
mechanism
In 1995 it could be shown that newly synthesized sulfatases
contain a crucial cysteine residue, which undergoes oxidation to a Cα-
formylglycine (FGly) residue [2] (Fig. 2). This unique and, up to now,
sulfatase-speciﬁc amino acid is generated by a post-translational
modiﬁcation occurring in the ER (Fig. 1) before the sulfatase
polypeptides fold into their native structure [109]. The presence of
FGly is obligatory for sulfatases to become catalytically active. It is
virtually undetectable in sulfatases isolated from MSD patient
ﬁbroblasts [2].
The essential requirement of this unusual amino acid could be
explained by functional and structural analyses of several human
sulfatases and also type I bacterial sulfatases [110], which were shown
to contain FGly as well [111,112]. In particular the crystal structures of
arylsulfatase A with and without bound substrate [3,113] and, most
convincingly, the high-resolution structure of a sulfatase from Pseu-
domonas aeruginosa [4] demonstrated that FGly forms an aldehyde
hydrate with two geminal hydroxyls acting as the catalytic residue at
the active site. Both hydroxyl groups are strictly required for catalysis
pursuing a unique hydrolytic mechanism. According to this so-called
transesteriﬁcation/elimination mechanism (Fig. 2), one hydroxyl
group performs a nucleophilic attack onto the substrate sulfur and
covalently binds the sulfate group forming an enzyme sulfate ester. The
second hydroxyl is required to induce elimination of the sulfate from
theenzymevia an ‘intramolecularhydrolysis’ in order to regenerate the
free aldehyde group of FGly (Fig. 2) [3,4]. A serine mutant (with only
one hydroxyl) can catalyze the transsulfation step leading, however, to
a dead-end sulfated enzyme, because sulfate elimination is not
accomplished due to lack of the second hydroxyl [114].
4.2. FGly generation — a speciﬁc post-translational modiﬁcation during
early sulfatase biogenesis
The conversion of the cysteine to FGly is directed by the rather
simple linear sequence motif CxPxR, which is part of the so-called
sulfatase signature I (C-[STACG]-P-[STA]-R-x(2)-[LIVMFW](2)-[TAR]-
G) (PROSITE database) located in the N-terminal catalytic domain of
the sulfatases. Within this signature the proline and the arginine in
+2 and+4 position, respectively, are the only essential residues apart
from the cysteine itself, which determine FGly modiﬁcation [115,116].
Table 2
Human sulfatases, their intracellular localization, physiological substrates and associated genetic disorders
Sulfatase Abbr. Chromosomal localization Physiological substrate Subcellular localization Associated genetic disorder, OMIM#
Arylsulfatase A ASA 22q13.31-qter Cerebroside-3-sulfate Lysosomal Metachromatic leukodystrophy (MLD), #250100
Arylsulfatase B ASB 5q11–q13 CS/DS Lysosomal Maroteaux–Lamy syndrome (MPS VI), #253200
Arylsulfatase C (steroid sulfatase) ASC, STS Xpter-p22.32 Steroid sulfates ER/microsomal X-linked ichthyosis (XLI), #308100
Arylsulfatase D ASD Xp22.3 Unknown ER Unknown
Arylsulfatase E ASE Xp22.3 Unknown Golgi Chondrodysplasia punctata 1 (CDPX1), #302950
Arylsulfatase F ASF Xp22.3 Unknown ER Unknown
Arylsulfatase G ASG 17q24.2 Unknown Lysosomal Unknown
Arylsulfatase H ASH Xp22.3 Unknown Unknown Unknown
Arylsulfatase I (Sulf5) ASI 5q32 Unknown Unknown Unknown
Arylsulfatase J (Sulf4) ASJ 4q26 Unknown Unknown Unknown
Arylsulfatase K (Sulf3) ASK 5q15 Unknown Unknown Unknown
Galactosamine 6-sulfatase GalN6S 16q24.3 CS, KS Lysosomal Morquio A syndrome (MPS IVA), #253000
Glucosamine 6-sulfatase GlcN6S 12q14 HS, KS Lysosomal Sanﬁlippo D syndrome (MPS IIID), #252940
Heparan N-sulfatase (sulfamidase) GlcNS, SGSH 17q25.3 HS Lysosomal Sanﬁlippo A syndrome (MPS IIIA), #252900
Iduronate 2-sulfatase IdoA2S Xq28 HS, DS Lysosomal Hunter syndrome (MPS II), #309900
Sulfatase 1 Sulf1 8q13.3 HS Cell surface Unknown
Sulfatase 2 Sulf2 20q13.12 HS Cell surface Unknown
(CS/DS, chondroitin sulfate/dermatan sulfate; HS, heparan sulfate; KS, keratan sulfate; MPS, mucopolysaccharidosis; OMIM#, Online Mendelian Inheritance in Man catalog number,
John Hopkins Unversity, http://www.ncbi.nlm.nih.gov/).
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conserved in human sulfatases ([LIMW]TG), fulﬁlls an auxiliary
function for proper presentation of the CxPxR core motif. In fact,
introducing the CxPxR motif into engineered recombinant proteins
leads to FGly generation in eu- and prokaryotic expression systems
[109,117]. Thus, FGly formation occurs while the protein is still largely
unfolded. In mammals it represents a late co- or early post-
translational modiﬁcation occurring in the lumen of the ER, as could
be shown by studying import intermediates of de novo synthesized
sulfatase polypeptides with and without ribosome (and translocon)
association [109,118]. In these in vitro experiments, FGly modiﬁcation
occurred after the critical cysteine had passed the translocon-
associated oligosaccharyl transferase responsible for co-translational
N-glycosylation. Nevertheless, FGly modiﬁcation was more efﬁcient
under co-translational than under post-translational conditions, as
held true even in a membrane-free assay [109,118].
4.3. Deﬁciency of an ER enzyme leads to combined lysosomal storage and
other disorders
The ER-resident enzyme catalyzing this modiﬁcation reaction was
discovered in 2003, as described below in further detail, and was
termed FGly-Generating Enzyme (FGE). All MSD patients analyzed so
far carried mutations in the gene encoding FGE (see below). Thus,
multiple sulfatase deﬁciency may be re-deﬁned as FGE deﬁciency. The
resulting defect of FGly modiﬁcation affects all sulfatases, as could be
veriﬁed recently in a MSD mouse model [119] (see below).
Sulfatases represent a family of hydrolytic enzymes essential for
the degradation and remodeling of sulfate esters. In mammals,
sulfatases are involved in the turnover of various sulfated substrates
such as glycosaminoglycans (heparin, heparan sulfate, chondroitin/
dermatan sulfate, keratan sulfate), steroid hormones (e.g. dehydroe-
piandrosteron 3-sulfate) and sulfolipids (e.g. cerebroside-3-sulfate)
[100,120] (Table 2). Furthermore, they have important regulatory
functions in modulating heparan sulfate dependent cell signaling
pathways [121–127] as well as in the activation of sulfated hormones
during biosynthesis [128,129]. In vivo, sulfatases display stringent
speciﬁcities towards their individual substrates and have low
functional redundancy.
Thirteen of the 17 sulfatases encoded in the human genome have
been characterized biochemically [130]. Based on their subcellular
localization they can be divided into lysosomal and non-lysosomal
enzymes (Table 2). The latter are found either at the cell surface (Sulf1,
Sulf2), in the endoplasmic reticulum (arylsulfatases C, D and F) or in
the Golgi apparatus (arylsulfatase E) and act at neutral pH. In contrast,all lysosomal sulfatases (arylsulfatases A, B and G, iduronate 2-
sulfatase, heparan N-sulfatase, glucosamine 6-sulfatase and galacto-
samine 6-sulfatase) share an acidic pH optimum [131]. Arylsulfatase G
has been discovered only recently as a lysosomal sulfatase [132]; so far
no disorder has been associated with this sulfatase. The genetic
deﬁciency of each of the other six lysosomal sulfatases causes speciﬁc
and severe lysosomal storage disorders, namely metachromatic
leukodystrophy (MLD) and mucopolysaccharidoses type II, IIIA, IIID,
IVA and VI (Table 2), which highlights the essential and non-
redundant function of these enzymes [120]. In affected patients, the
degradation of a speciﬁc sulfated compound is blocked, leading to its
accumulation in lysosomes and extracellular ﬂuids. Lysosomal storage
impairs autophagic delivery of bulk cytosolic contents to lysosomes,
ﬁnally resulting in accumulation of toxic proteins, cellular damage and
apoptosis [133]. Two non-lysosomal human sulfatases could be
related to single sulfatase deﬁciencies, namely arylsulfatase C (also
termed steroid sulfatase) to X-linked ichthyosis and arylsulfatase E to
chondrodysplasia punctata type 1 [120] (Table 2).
4.4. Clinical features and diagnosis
Patients suffering from MSD combine clinical symptoms of the
different single sulfatase defects. As a major sign they show a
neurodegenerative course of disease with loss of sensoric and motoric
abilities similar to MLD and neurological deterioration. Mental
retardation, hepatosplenomegaly, shortening of stature and corneal
clouding appear like in different mucopolysaccharidoses. In addition,
ichthyosis and skeletal changes similar to chondrodysplasia punctata
type I could be found [100,134,135].
The combination of different clinical symptoms and also the time
of appearance differ among MSD patients. These differences allow for
a classiﬁcation of disease types. MSD can be subdivided into neonatal
very severe, late infantile severe, late infantile mild and juvenile cases
[100,134,136]. A variant infantile form of MSD was published as the
Saudi-variant of MSD [137]. Patients can be classiﬁed by comparing
ten different clinical symptoms appearing in MSD and their time of
onset (Table 3). The few described neonatal very severe cases were all
diagnosed shortly after birth because of the typical combination of
different symptoms resembling several of themucopolysaccharidoses.
The affected children died within the ﬁrst year [138–141]. In contrast,
all other described clinical cases showed a slower progression of
disease with a neurodegenerative course comparable to late infantile
metachromatic leukodystrophy, clearly and obviously differing from
neonatal very severe cases [142–144]. Severe infantile cases of MSD
could be distinguished from mild cases by the earlier onset of
Table 3
Classiﬁcation of MSD patients and associated clinical phenotype
Symptoms/disease
type
Neonatal very
severe
Late infantile
severe
Late infantile
mild
Juvenile
mild
Retardation +++ +++ +++ ++
Neurodegeneration/
neurological symptoms
+++ +++ +++ ++
Ichthyosis +++ +++ ++ +
Dysmorphism +++ +++ − +
Organomegaly +++ +++ − −
Skeletal changes +++ ++ + −
Intrauterine
manifestation
+++ +++ − −
Heart disease +++ − − −
Corneal clouding +++ − − −
Hydrocephalus +++ − − −
Four different MSD subtypes, subdivided by the appearance of ten different symptoms
present in MSD and their time of onset, can be distinguished. The severity of cases
ranges from neonatal very severe forms with the onset of all of the ten symptoms
shortly after birth to mild cases with selected symptoms appearing later in life (age at
onset: +++ b2 years, ++ 2–4 years, + N4 years, − not observed).
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symptoms, most of them being recognized at two to four years of age
and beyond (Table 3). Only rare cases of juvenile MSDwere published.
The affected patients showed selected symptoms ofMSD, appearing in
early childhood [100, 134, 135, 137,145,146].
Also biochemically, MSD is distinct and classiﬁable. Patients with
MSD show amixed excretion of glycosaminoglycans and storage of the
different sulfatase substrates [147,148]. The residual activities of
different sulfatases measured in leukocytes and ﬁbroblasts of patients
can be sub-grouped into two classes with less than 15% compared to
normal activities into group I and more than 15%, sometimes reaching
normal values, into group II [149–152]. Clinically, group I reﬂects
severe cases of MSD, whereas group II activities correspond to milder
cases [138,153]. The reason for differences in residual activities of the
individual sulfatases in the same patient between very low and nearly
normal values is still unclear. A possible explanation could be a
difference in the afﬁnity of mutant FGE towards different sulfatase
polypeptides. One important observation in terms of MSD diagnosis is
the fact that residual sulfatase activities can vary due to different cell
culture conditions and time points of measurement [151,154,155].
Group II ﬁbroblasts seem to be more sensitive to this kind of change
than group I ﬁbroblasts [136].
The combination of the most important clinical symptoms
neurodegeneration, dysmorphic signs reminding one of the mucopo-
lysaccharidoses, and ichthyosis validates the clinical diagnosis of MSD.
The presence of demyelination similar toMLD, shown by hyperintense
magnetic resonance imaging signals in the posterior periventricular
and subcortical white matter, hepatosplenomegaly, pathological X-ray
examinations suggestive of chondrodysplasia and bone deformation,
lysosomal storage in different tissues and excretion of different
glycosaminoglycans are additional paraclinical signs of MSD
[100,134,135]. MSD is veriﬁed by the measurement of decreased
activities of different sulfatases in leukocytes, in addition to cultured
ﬁbroblasts, as sulfatase activities can differ due to cell culture
conditions [103,142,145,148,151,154,156], and by sequencing of the
SUMF1 gene [144,157–159]. Pitfalls in the diagnosis of MSD are a
sequential appearance of leading clinical features, which delays the
diagnosis [142]. Prenatal testing for MSD is possible.
5. FGE — the MSD enzyme
5.1. Initial characterization of enzymatic activity
Based on the key ﬁnding that the generation of formylglycine
(FGly) in the active site of sulfatases is defective in sulfatases from
MSD patients [2], it became the pivotal aim to identify the enzyme,which catalyzes this unique amino acid modiﬁcation. Soon after the
discovery of FGly we could show by in vitro translation/translocation
experiments that newly synthesized sulfatases receive their FGly
modiﬁcation during or soon after translocation into the ER [109,160]
and that the FGly generating machinery recognizes a short linear
CxPxR motif conserved among sulfatases (see above) [115]. FGly
formation was found to be an enzyme-mediated reaction that occurs
in the reticuloplasm, the soluble matrix of the ER [118]. Synthetic
arylsulfatase A-derived peptides containing the CxPxR motif compe-
titively inhibited sulfatase modiﬁcation. In vitro, the enzyme is active
at a broad pH rangewith an unusual alkaline optimum at pH 9–10, and
depends on the presence of reducing agents such as glutathione or
dithiothreitol [118] (see below). Measuring FGly formation in a
membrane-free assay paved the way to develop and apply simple
puriﬁcation protocols. This assay employed in vitro synthesized
sulfatase substrates that, after incubation with ER-derived fractions,
were analyzed at the level of its tryptic peptides by a combination of
reversed-phase HPLC, chemical derivatization of the formyl group and
mass spectrometry [118,161]. Each single sample had to be subjected
to a laborious one-week procedure that, despite the low throughput,
for many years formed the basis to follow the modiﬁcation activity
after chromatographic separation of reticuloplasm proteins.
5.2. Discovery of the gene and protein underlying MSD
In 2003, thegeneencoding the FGly-modifying factorwas identiﬁed
independently by our group [157] and by the group of Andrea Ballabio
[158]. The two approaches to ﬁnd the gene, however, were rather
different. In our biochemical approach, we ﬁrst had to develop a fast,
straightforward method to assay FGly-generating activity. This was
achieved by using a 23mer peptide substrate (P23), containing the
dodecamer sulfatase signatureof arylsulfataseA(CTPSRAALLTGR), and
MALDI-TOFmass spectrometry to quantify substrate and product after
the reaction [157]. The assay was used to detect enzyme activities
during puriﬁcation starting from reticuloplasm of bovine testis
microsomes. The key chromatographic step during a four-column
procedure was the afﬁnity chromatography with the P23-related
peptide ASA65-80-C69S as immobilized ligand. It proved to be
essential to substitute the critical cysteine 69 of the ASA65-80 peptide
by serine, because under the applied conditions the enzyme is
inactivated by the wild-type peptide (B. Schmidt, unpublished). The
eluate after SDS-PAGEshowedtwobandsof about39and41kDa,which
were identiﬁed by peptide mass ﬁngerprint analysis as full-length and
N-terminally truncated versions of the same gene product that
matched with a bovine EST database entry. The human gene ortholog
(92% identity between the corresponding mature proteins) is located
on chromosome 3p26.
Cosma et al. identiﬁed the same gene by means of functional
complementation of an immortalized human MSD cell line using
microcell-mediated chromosome transfer [158]. A panel of human/
mouse hybrid lines containing individual human chromosomes was
fused to theMSD cells and the result of complementationwas analyzed
bymeasuring sulfatase activities in cell lysates. Complementationwith
the complete chromosome 3 was shown to rescue sulfatase activities.
To narrowdown the chromosomal localization of the responsible gene,
irradiation microcell-mediated chromosome transfer was performed.
Many chromosome 3 irradiated hybrids were tested for sulfatase
activities and genotyped until the complementing gene could be
mapped to a 2.4 Mb chromosomal region at position 3p26. When the
genes located in the complementing region were scanned for
mutations in MSD patients, one gene was found to contain mutations
in all patients tested [158]. The two groups agreed to name the gene
sulfatase modifying factor 1 (SUMF1) and the encoded protein was
denoted formylglycine-generating enzyme (FGE). To verify the
sulfatase-activating function of FGE, a number of mammalian cell
types were co-transfected with FGE and sulfatase encoding cDNAs.
Fig. 3. Basic architecture of FGE. Full-length FGE (top) and N-terminally truncated FGE (bottom), which results from furin-like processing in the Golgi, are largely made up of the
globular DUF 323 domain (dark green). This domain is stabilized by two permanent disulﬁde bridges, as indicated (with positions of the involved cysteines given in red). C336/C341
is the redox-active cysteine pair of the catalytic site. Furthermore, truncated FGE lacks the N-terminal extension present in full-length FGE with the conserved cysteine pair C50/C52,
which forms intermolecular disulﬁdes and is required for FGly generation in vivo [162, 164] (see text). This N-terminal extension further confers ER retention of FGE through
interaction with the RDEL-protein ERp44 (see text). The N-linked glycan, indicated as a tri-antennar sugar tree (in blue), belongs to the high-mannose type, but is processed further
upon trafﬁcking past the ER [162].
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activities were increased up to 50-fold. Most importantly, endogenous
sulfatase activities in cells from MSD patients could be restored by
retroviral transfer of the SUMF1 cDNA. These ﬁndings emphasize the
essential and limiting role of FGE in the activation of sulfatases as well
as the monogenetic nature of MSD [157, 158].
5.3. Biochemistry and cell biology of FGE
The SUMF1 gene has a size of about 106 kb and contains 9 exons
coding for a protein of 374 amino acids. FGE is expressed ubiquitously,
with the highest mRNA levels in pancreas and kidney. Intracellularly,
FGE is localized in the ER where it fulﬁlls its enzymatic function
[157,158,162]. In cultured cells, however, a variable fraction of FGE is
also secreted into the medium, as can be detected even at endogenous
expression levels [6,162]. ER targeting is accomplished through an N-
terminal signal sequence of 33 residues. After signal peptide cleavage,
mature intracellular FGE has a size of 41 kDa consisting of two
domains. The core domain, forming the largest part of FGE (residues
91–374), is highly conserved in both pro- and eukaryotes [157,163]
(Fig. 3). The N-terminal extension (residues 34–90), which probably
forms a separate domain, is only found in eukaryotes, where it serves
essential functions in vivo (see below). Asparagine 141 carries a
carbohydrate side chain of the high mannose type. Eight cysteines
form four disulﬁde bridges; the N-terminal cysteine pair C50/C52 and
the more C-terminally localized pair C336/C341, however, were also
found in reduced form (Fig. 3).
When FGE is secreted, the carbohydrate chain is modiﬁed to the
complex-type and in the majority of molecules a stretch of 39 amino
acids (residues 34–72) is cleaved off from the N-terminus by a furin-
like protease in the Golgi [162, M. Mariappan, unpublished data] (Fig.
3). Both, full length and the secreted N-terminally truncated FGE were
shown to modify sulfatase-derived peptides in vitro, indicating that
the globular domain of FGE contains the active site of the enzyme
[162]. In vivo, remarkably, the N-terminal extension of FGE and its
fully conserved pair of cysteines (C50/C52, Fig. 3) are required for
sulfatase activation, indicating a cooperation between the N-terminal
extension and the globular domain of FGE to perform its physiological
function [164]. Additionally, we found that the N-terminal extension is
also required for the retention of FGE in the ER [164]. In subsequent
studies it was shown that the retention of FGE is mediated by ERp44
[165,166], an ER protein known to retain other prominent ER proteins
by forming mixed disulﬁde bridges through its cysteine 29 residue.
The interaction of FGE and ERp44 involves the N-terminal extension of
FGE but is primarily non-covalent. Although a disulﬁde bridge
between Cys-29 of ERp44 and Cys-50 or 52 of the FGE N-terminal
extension can form to stabilize the complex, this mixed disulﬁde bond
turned out not to be required for retention [165].
Other ER proteins, namely ERp57, protein disulﬁde isomerase (PDI)
and pFGE, a paralog of FGE, as well as ERGIC-53, located at ER exit sites,
were also described to interact with FGE as detected by co-immunoprecipitation from FGE overexpressing HeLa cells [166].
However, their function is not fully understood as yet. Whereas
ERp57 and PDI also seem to contribute to retention of FGE, ERGIC-53
was shown to bind FGE at the oligosaccharide side chain, thereby
preventing proteasomal degradation of FGE — possibly by promoting
its progression along the secretory route. If true, this would indicate
that ERGIC-53 and ERp44 in functioning as ER export and retrieval
factors, respectively, contribute to a balanced control of FGE localiza-
tion [166]. Beside its function in retention of FGE, PDI seems to
participate, directly or indirectly, in the activation of sulfatases, as
suggested by co-overexpression of PDI and reporter sulfatases and
also by PDI silencing experiments [166].
The role of pFGE in sulfatase activation is also still unclear. This
protein shows a high homologywith FGE (47% identity) butmisses the
N-terminal extension and 6 of the 8 cysteines of FGE. It is coexpressed
together with FGE in many tissues, binds sulfatases, although with a
lower afﬁnity than FGE, but does not possess FGly generating activity
[167]. This inactivity can be explained merely by the fact that pFGE
lacks the catalytic cysteines 336 and 341 (see below). Overexpression
of pFGE together with FGE leads to a partial decrease of FGE-mediated
sulfatase activation, indicating a possible role in regulation of FGE
activity [167,168]. The hypothesis that pFGE,which is retained in the ER
via a non-canonical KDEL-type signal (PGEL), serves FGE retention
through pFGE/FGE complex formation turned out to be wrong [169].
As mentioned above, a low and variable amount of endogenous
FGE is secreted from cells into the medium. Further, it was shown for
different cell lines that secreted FGE can be taken up via mannose
receptor-mediated endocytosis [6]. Following uptake into MSD
ﬁbroblasts, FGE was found to reach the ER, leading to an increase of
sulfatase activity. Apart from the surprising paracrine function and
unusual trafﬁcking of FGE, this result is remarkable, as it suggests that
enzyme replacement therapy in principle is applicable for treatment
of MSD. Also gene therapy should be effective because secreted FGE
produced by transduced cells could allow metabolic cross-correction
[6] (see Section 8).
6. Crystal structure of FGE — towards an understanding of FGE
function and dysfunction in MSD
In 2005, we solved the crystal structures of secreted FGE (Fig. 4A)
[170] and its paralog pFGE [171]. We found both molecules to form a
single globular domain with a novel fold that is stabilized by two
calcium ions and has a remarkable low content of secondary
structures (20% β-sheets and 13% α-helices in FGE). In the crystal
of secreted FGE, lacking residues 34–72, the ﬁrst visible N-terminal
amino acid is Leu-86, fromwhere the globular domain extends to the
C-terminus. It contains six cysteines, four of which were disulﬁde-
bridged and two (Cys-336/Cys-341) partially in the reduced form
(Fig. 4A). Cys-336 and Cys-341 are both fully conserved and essential
for catalytic activity. They are localized in an oval-shaped groove,
which could be proven to form the active site of FGE, as shown by
Fig. 4. Crystal structure of FGE and molecular basis of MSD. (A) The globular domain of FGE (ribbon presentation) is shown in complex with the sulfatase-derived peptide LCTPSRA
(stick presentation in red and, for the critical cysteine, yellow). The stabilizing disulﬁde bridges of FGE (in yellow) and Ca2+ ions (gray spheres) are indicated as well as the redox-
active catalytic cysteines C336 and C341. (B)MSD-causing missensemutations aremapped onto the FGE structure and are colored according to the predicted or in some cases directly
proven effect [170, 136] on FGE structure and function (white, destabilizing; green, inhibition of substrate binding; orange, catalytically inactivating). The majority of the mutations
will prevent folding of FGE into its native conformation by destabilizing the hydrophobic core. Further destabilizingmutations are located at a tight surface loop (263 and 266) and at
Ca2+-site 1 (259). For further details see [170].
Fig. 5. Proposedmono-oxygenasemechanism of FGly generation in sulfatases. (1) Upon
activation of molecular oxygen by FGE cysteine sulfenic acid (–CH2S–OH) is generated
ﬁrst at cysteine C336 of FGE (not shown) and then, by hydroxyl transfer, at the critical
sulfatase cysteine residue. An external reductant, such as glutathione, is required for
this step to reduce the second oxygen of O2 to water. (2) Awater molecule is eliminated
from the cysteine sulfenic acid leading to the formation of an instable thioaldehyde
intermediate (–CHS). (3) This spontaneously hydrolyzes to the FGly aldehyde (–CHO).
For further details see [116,170].
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crystallization of the FGE mutant C336S with a LCTPSRA substrate
peptide (Fig. 4A) [172].
6.1. FGE — a metal-independent mono-oxygenase
The catalytic mechanism of FGly generation still bears unresolved
questions, but some aspects have been uncovered. Molecular oxygen
(O2) was found to be consumed equimolarly during generation of FGly
(J. Peng et al., unpublished data). The present data suggest that FGE is
a mono-oxygenase [170]. Strikingly, redox active metal ions or other
redox cofactors have not been detected — neither in the crystal
structure nor by plasma mass spectrometry of the active enzyme.
Apart from the artiﬁcial reductant dithiothreitol (see below), no such
factors need to be supplied to sustain multi-turnover FGly formation
activity in vitro. Consequently, FGE must employ a unique mechanism
to utilize molecular oxygen that is very different from the redox
chemistry seen in conventional oxygenases and dehydrogenases. This
mechanism obviously relies merely on cysteine redox chemistry of the
catalytic cysteine pair in the FGE active site, serving to transfer
oxidizing equivalents to the sulfatase substrate cysteine (Fig. 5).
In fact the two active site cysteines turned out to behave very
differently. On the one hand, Cys-336 is extremely prone to oxidation by
molecularoxygen, yielding sulfenic or, in vitro, even sulfonic acid. On the
other hand, Cys-341 forms a disulﬁde bridge to the substrate cysteine, as
seen in the FGE-C336S/peptide co-crystal [172] or in trapped catalytic
intermediates (B. Schmidt,unpublisheddata). Thus, it appears likely that
Cys-341 binds the substrate and Cys-336 oxidizes it [170].
After substrate binding, a small cavity is formed in the active site
surrounded by the three critical cysteines, i.e. the active site cysteine
pair of FGE and the substrate cysteine. The size and location of this
cavity accommodates the essential oxygen molecule in a way that it is
close to all three cysteine residues. The cavity is shielded from bulk
solvent, excluding the entry of further oxygen to avoid overoxidation
of Cys-336 [172,173].A simpliﬁed mechanism for FGly generation, focusing only on the
chemistry at the sulfatase substrate cysteine, is proposed in Fig. 5. The
oxygenmolecule is cleaved by FGE and one oxygen atom is reduced to
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(–CH2S–OH) ﬁrst at Cys-336 of FGE, fromwhere the OH-group is then
transferred onto the critical cysteine of the sulfatase (Fig. 5, step 1). O2
reduction requires the supply of four electrons, two from the sulfatase
cysteine and two from an external reductant. Elimination of a water
molecule from the cysteine sulfenic acid forms a thioaldehyde (step
2), which undergoes spontaneous hydrolysis to the aldehyde via a
thioaldehyde hydrate intermediate (step 3). FGE catalyzes the
reaction (i) by binding the unfolded substrate polypeptide in the
active site, possibly involving formation of a disulﬁde bridge between
Cys-341 and the substrate cysteine, (ii) by activating molecular
oxygen independent of redox-active metal ions, probably via Cys-336
sulfenic acid (step 1) and (iii) by β-elimination of a water molecule
from the cysteine sulfenic acid (step 2) most likely through Ser-333
mediated proton abstraction from the β-carbon (for details see [170,
172]). As a reductant in step 1 dithiothreitol can be used in in vitro
assays. The physiological reductant, however, is still unknown.
6.2. A general mechanism for sulfatase binding and speciﬁcity
The co-crystallized FGE–peptide complexes delineate the general
substrate-binding mode used by FGE for all human sulfatases during
their maturation. The high conservation of the CxPxR motif in
eukaryotic andmost prokaryotic sulfatases indicates that all sulfatases
are bound to and modiﬁed by FGE using the same mechanism. The
binding of the key proline and arginine residues, in central and
terminal position of the CxPxR consensus, respectively, involves
pockets of high hydrophobic surface or electrostatic complementarity,
respectively [172,174]. Accordingly, the FGE substrate binding site
displays exquisite sensitivity to alterations in the sulfatase sequence as
seen by scanning mutagenesis [115] and by natural mutations in
human arylsulfatase B, heparan N-sulfatase, galactosamine 6-sulfatase
and iduronate 2-sulfatase, all of which lead to mucopolysaccharidoses
(summarized in [172]). As the mutated sulfatases most likely fail to
bind to FGE and are therefore not modiﬁed, manifestation of these
diseases in the affected patients further corroborates that the ﬁve
residues of the human C-[TSAC]-PSRmotif are necessary and sufﬁcient
for speciﬁc FGE/sulfatase interaction.
6.3. Molecular basis of MSD
Until today, 30 mutations were found in the SUMF1 gene, which
lead to different MSD phenotypes. 21 of these mutations are missense
mutations appearing in homozygosity or compound heterozygosity.
The remainingmutations are deletions of single nucleotides leading to
frameshifts and premature stops of the FGE protein, larger deletions,
splice site mutations and stop mutations (p.R327X, p.S359X). Two of
the missense mutations affect the N-terminal methionine, leading to
failure of translation initiation or, in case that the downstream in-
frame methionine-91 codon would be used, to production of FGE
lacking the N-terminal 90 residues. Another mutation (L20F) affects
the hydrophobic core of the signal sequence. The remaining 18
missense mutations affecting residues visible in the crystal structure
were mapped onto the FGE fold to predict structural consequences
leading to impaired function of the enzyme (Fig. 4B) [170].
According to their predicted effects on FGE themissensemutations
could be divided into three groups: i)Most of themutations destabilize
the protein structure by hampering efﬁcient packaging of the protein
core or by loss of important side chain interactions (Fig. 4B). Two
missense mutations with high allele frequency belong to this group:
c.1045CNT (p.R349W) appearing in patients of Turkish origin and
c.836CNT (p.A279V) appearing in patients of French and French-
Canadian origin. Anothermutant, p.N259I, abolishes the bindingof one
of the calcium ions,which contribute to the stability of the protein fold.
ii) A second group of mutations lead to interference with substrate
binding. This prediction is veriﬁedby twoMSD-causing FGEmutations,namely p.A177P and p.W179S, which both are located in a loop region
near the substrate binding site (Fig. 4B). The FGE–peptide complex
structure conﬁrmed that positions 177 and 179 are indeed close to the
boundpeptide [172]. iii) The third groupofmutations leads to impaired
catalytic activity. This group is represented by the mutant p.C336R,
which is a null mutant [170,175] because arginine replaces one of the
essential active site cysteines directly involved in the catalysis of FGly
generation. These predictions on the basis ofmolecularmodelingwere
proven for a number of mutants by expression and analysis of the
mutant proteins (see below).
7. Genotype–phenotype correlation in MSD — potential
and limitations
The discovery of the SUMF1 gene, the determination of the FGE
crystal structure and, most recently, the creation of a SUMF1 gene trap
(SUMF1Gt)mousemodel allowed one to look closer into the molecular
basis underlying MSD and further, to deﬁne and test molecular
parameters with possible impact on disease severity. The basic
observations are summarized as follows. Transduction of MSD
ﬁbroblasts with wild-type SUMF1 cDNA more or less fully restored
the activities of different sulfatases in these cells [157,158]. Further,
overexpression of different MSD-causing FGE mutants in patient cells
or murine SUMF1Gt cells led to a correct or at least partially correct
localization in the ER for all mutant FGEs analyzed so far [136,175,176].
Importantly, expression of FGE missense mutants in SUMF1Gt cells
directly inﬂuenced endogenous sulfatases leading to an increase of
sulfatase activities, albeit to a much lower extent as compared to
expression of wild-type FGE. In contrast, untransduced SUMF1Gt cells
(or those transduced with the null mutant p.C336R) showed no
sulfatase activities [175]. Furthermore, it is a common ﬁnding that
MSD patients exhibit detectable, albeit low or even very low residual
sulfatase activities. Thus, MSD-causing mutations, at least in non-
neonatal cases, are hypomorphic. A complete loss of FGE function is
supposed to lead to embryonic or neonatal lethality in human [175].
Accordingly, SUMF1Gt mice show high mortality in the ﬁrst weeks of
life, though 10% reach three months of age [119]. High embryonic/
neonatal lethality is also observed in mice with a knock-out of only
two sulfatases, namely the non-lysosomal sulfatases Sulf1 and Sulf2
[121,177]. These cell surface endo-sulfatases (Table 2) modulate
important cell signaling pathways underlying differentiation and
development via speciﬁc 6O-desulfation of cell surface heparan
sulfate proteoglycans [121,178]. Thus, developmental problems seem
to be a contributing, if not the primary cause for early fatality in
neonatal MSD.
Given the hypomorphic nature of the majority of MSD-causing
mutations, resulting in residual functionality of the expressed mutant
versions of FGE, the question arises whether a genotype-phenotype
correlation exists in MSD. For prognosis of the outcome of the disease,
until today only the clinical as well as the biochemical classiﬁcation of
different types of MSD (see Section 4.4) can be taken into considera-
tion. A predictable genotype–phenotype correlation is complicated by
the fact that 17 defective sulfatases contribute to the complex clinical
phenotype in MSD, each of which most likely gives rise to a
compensatory response. When attempting to explain the differences
in MSD manifestation from the molecular ﬁndings, the key approach
must be to deﬁne the residual functionality of the relevant FGE
mutants expressed in patients.
Indeed, one can deduce some principle mechanisms in MSD that
inﬂuence the clinical phenotype. SUMF1 mutations in patients with a
neonatal very severe course of disease were either nonsense
mutations with large deletions, frameshift mutations or missense
mutations directly affecting the active site of FGE (like p.C336R, see
above). Further, a functional characterization of different MSD causing
FGE missense mutations found in homozygosity (or in combination
with a frame-shift null allele) in MSD patients (p.A177P, p.W179S, p.
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for three mutants (A177P, W179S, R349W) and also impaired protein
stability for two of the mutants (A279V, R349W) [136], thereby
conﬁrming the functional consequences of missense mutations on the
FGE protein, as predicted from the crystal structure (see Fig. 4B) [170].
Interestingly, residual sulfatase activities in ﬁbroblasts from patients
carrying the investigated mutations in homozygosity were extremely
reduced only in case of mutation R349W leading to both protein
instability and very low residual FGE activity (group I ﬁbroblasts).
Patients with this homozygous mutation all show a late infantile
severe phenotype. On the other hand, ﬁbroblasts with either stable
proteins and low residual FGE activity (A177P, W179S) or instable
proteins with high residual FGE activity (A279V) exhibited just
slightly reduced sulfatase activities (group II ﬁbroblasts). Accordingly,
patients with these mutations show a milder course of disease [136].
Taken together, both residual FGE activity and protein stability seem to
determine the severity of disease manifestation in MSD. More data on
further mutations are necessary to validate this approach and to
obtain a better understanding of genotype/phenotype correlations in
MSD. The available data, however, already now suggest that the direct
analysis of mutant FGE activity and stability might allow a more
reliable biochemical classiﬁcation, as compared to the more indirect
sulfatase activity determinations in patient cells, which in group II
ﬁbroblasts have proven to depend on cell culture conditions (see
Section 4.3). The ﬁndings, however, do not exclude that secondary
factors or modiﬁer genes, unspeciﬁed as yet, play a role in determining
disease manifestations. In particular for milder mutations these
factors may obscure reliable prognosis.
8. The SUMF1 gene-trap as a mouse model for
therapeutic approaches
Recently, Settembre et al. described a mouse model for MSD that
was generated from an ES cell clone with a gene-trapped SUMF1 allele
[119]. The homozygous SUMF1Gt mice show a complete loss of
sulfatase activity, as tested for eight different sulfatases in various
tissues, thus proving that FGE represents the only system for FGly
generation in mammals. As mentioned, total loss of sulfatase activity
in SUMF1Gt mice further indicates that MSD-causing SUMF1mutations
in human are hypomorphic, since all MSD patients exhibit at least very
low residual sulfatase activities [119].
The SUMF1Gt mice display congenital growth retardation and
frequent early mortality, with 10% reaching the age of 3 months. A ﬂat
facial appearance as well as skeletal abnormalities was visible. The
mice manifested head tremor and seizures due to defects of the
central nervous system. Histologically, glycosaminoglycan staining
was detected in liver, kidney and, as a prime site, in macrophages
which were massively present in all tissues. These macrophages and
activated microglia in cerebellum and cortex, accompanied by
neuronal cell loss and astroglyosis, indicate systemic and neuroin-
ﬂammation, which are thought to be key pathophysiological processes
in MSD [119].
The SUMF1Gt mouse model not only allows a systematic study of
the pathophysiology of MSD; importantly, it also provides a model to
test therapeutic approaches to the treatment of MSD, similar to other
mouse models of individual lysosomal storage disorders. A ﬁrst
approach of gene-therapy in this mouse model was highly interesting.
When Flag-tagged FGE was expressed in the SUMF1Gt mouse using
liver-speciﬁc expression via an adeno-associated viral vector, Flag-
tagged FGE protein and also increased sulfatase activity could be
determined in the liver and, surprisingly, also in other organs like lung
and kidney [6]. The transduced liver cells expressed and, in addition,
secreted functional FGE, which obviously was taken up by other
tissues leading, most remarkably, to partial restoration of sulfatase
activities in the recipient cells. Zito et al. could show in vitro that
secreted FGE obviously is taken up by other cells, where it is correctlytargeted back to the ER [6]. Importantly, also in this case FGE was able
to enhance sulfatase activities signiﬁcantly.
Thus, enzyme replacement therapy (ERT) with puriﬁed recombi-
nant FGE could be one therapeutical option. Nevertheless, like in other
LSDs, the blood-brain barrier poses an important difﬁculty for ERT and
makes intrahecal application necessary [179]. Alternatively, ERT with
a mixture of lysosomal sulfatases could, at least theoretically,
represent another therapeutic option. In this case, however, only
lysosomal sulfatases could be substituted, since ER or Golgi resident
sulfatases would probably not reach their intracellular place of action
if administered in ERT.
In contrast, gene therapymight serve to distribute functional SUMF1
cDNA within affected patients and to restore all sulfatase activities.
However, despite encouraging results for other LSDs and forMSD in the
SUMF1Gt mice (see above), a major therapeutical breakthrough in
human is still to be achieved [180]. Bone marrow transplantation as
well as inﬂuencing protein folding by the use of small molecules as
pharmaceutical chaperones, such as isofagomine in case of Gaucher
disease [181], are other yet unproven methods of MSD treatment.
Whatever therapy is considered,developmentaldefects causedbySulf1
and Sulf2 deﬁciency already during embryonic stages cannot be
reversed by any postnatal treatment. Nevertheless, the SUMF1Gt
mouse will provide important information about the feasibility and
efﬁcacy of any MSD therapy to be developed in the future.
9. FGE as a tool for therapy of single sulfatase deﬁciencies
For a number of LSDs, enzyme-, cell- and gene-based therapy
protocols have been developed, among them those LSDs caused by
single sulfatase deﬁciencies, namely MLD, MPS-II, -IIIA, -IIID, -IVA and
-VI. While various studies have been carried out using patient cells or
mousemodels for all these diseases, clinical trials havebeenperformed
only forMPS-II and -VI, [182–186], forwhich ERThas been successful in
both cases. FGE as the essential sulfatase activator plays a fundamental
role for industrial production of recombinant sulfatases to be used in
ERT but also when attempting cross-correction using gene therapy
strategies. For both approaches the beneﬁcial role of SUMF1 co-
expression with the sulfatase structural gene or cDNA have recently
been demonstrated [7,187–190].
In proof-of-principle experiments Fraldi et al. have used AAV and
lentiviral vectors for the co-delivery of sulfatase and FGE-encoding
cDNAs into cells from patients or from murine models with MLD,
MPS-II, MPS-IIIA or MPS-VI [189]. In all cases FGE enhanced sulfatase
activity resulting in improved clearance of sulfolipid or glycosami-
noglycan accumulation. Thus, co-delivery of FGE-encoding cDNAwith
the respective sulfatase cDNA seems demanding in gene therapy of
single sulfatase deﬁciency disorders.
Two papers verifying this concept for treatment of the MLD
mouse [188] and the MPS-IIIA mouse [190] were published recently
demonstrating that co-expression of FGE clearly improves the
efﬁcacy of gene therapy using either injection into the tail vein
[187] or, most important for diseases mainly affecting the central
nervous system, into the brain [188,190]. In the MLD mouse, FGE co-
expression not only improved ASA activity in the targeted tissue but
also, and even more pronounced, in the serum after intravenous
injection. Furthermore, after intracerebral injection in adult MLD-
mice the ASA activity was shown to be improved in the non-injected
hemisphere of the brain as well [188]. High serum or cerebrospinal
activities are of particular relevance when attempting to cross-
correct an enzyme deﬁciency in all tissues. To this end, transduced
producer cells have to secrete high activities of lysosomal sulfatases
that can be taken up via the mannose 6-phosphate receptor into non-
transduced cells causing correction also there. As a consequence,
after treatment of MLD mice marked reduction of sulfatide storage
was observed throughout the entire brain leading to improvement of
neurological functions [188].
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cerebral co-delivery of both heparan N-sulfatase and FGE-encoding
cDNAs into the lateral ventricles of newborn MPS-IIIA mice, a model
for another LSD mainly involving the brain and in fact the most
common of the MPS disorders. Although FGE co-expression improved
heparan N-sulfatase activity only 1.5-fold in the brain, as compared to
delivery of heparan N-sulfatase cDNA alone, a reduction of brain
pathology and an improvement of the behavioral phenotype, affecting
motor and cognitive functions, were observed [190]. It should be
emphasized, however, that in these studies pathological storage
reduction was achieved only in the brain areas which were efﬁciently
transduced by the AAV vector.
Despite a number of remaining problems, also for the treatment of
MLD mice [191], which will be potentiated in case of treating the
much larger human brain, sulfatase plus FGE co-expression from AAV
vectors represents a highly promising approach on the way towards
clinical trials. On the other hand, ERT protocols already now have been
applied successfully in patients of MPS-II and -VI [182–186]. Given the
ﬁnding that FGEmassively enhances sulfatase activities in a number of
overexpressing sulfatase producer cell lines, it is our hope that large-
scale production of highly active sulfatases will be much facilitated, so
as to allow for more efﬁcient and also much broader applications in
the near future. Indeed, encouraging results were obtained recently
for MPS-IVA, an LSD without involvement of the brain, for which
initial ERT studies in a mouse model have been successful after
administration of galactosamine 6-sulfatase produced by FGE-coex-
pressing cells [7].
10. Conclusions
MSD, ML II/III and NPC1 show complex disease manifestations
with lysosomal storage as the prime cellular defect that initiates
manifold organic dysfunctions. The non-lysosomal localization of the
affected proteins and, in the case of MSD and ML II/III, the pleiotropic
consequences on many lysosomal enzymes resulting from defective
post-translational modiﬁcations has intrigued cell biologists and
biochemists for many decades. The identiﬁcation and characterization
of the affected gene product not in all cases paved the way to
understand the basic causal relationships leading to the manifestation
of the disorder. This becomes particularly obvious in the case of NPC1
disease, where the true function of the NPC1 membrane protein is not
understood. For GlcNAc phosphotransferase the enzymatic function is
clear, but the mechanism of how it recognizes newly synthesized
proteins with a lysosomal destination remains to be unraveled at the
molecular level. For both issues, detailed functional studies using
reconstituted in vitro systems with deﬁned substrates, and also
structural analyses of apo- and substrate-bound proteins are
ambitious perspectives that certainly would bring major advance-
ments, as had been the case for understanding FGE and its role in
MSD. For the latter disorder, the most demanding questions relate to
the metal-free mono-oxygenase mechanism of FGE function and the
involvement of other components and redox factors of the ER in
sulfatase activation as well as the unusual trafﬁcking pathways
employed by FGE. Clariﬁcation of these aspects may each provide
hints for therapeutic approaches in order to either enhance residual
FGE activity, which is detectable in all MSD patients, or to effectively
envisage enzyme replacement therapy. For all three syndromes it
must be an ultimate goal to develop gene therapy towards clinical
application in order to permanently equip patients with functional
copies of their defective genes.
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